X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs SUN PHARMA - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS SUN PHARMA NOVARTIS/
SUN PHARMA
 
P/E (TTM) x 334.0 38.2 874.3% View Chart
P/BV x 37.0 4.1 908.5% View Chart
Dividend Yield % 1.2 0.3 398.4%  

Financials

 NOVARTIS   SUN PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-18
SUN PHARMA
Mar-18
NOVARTIS/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs758701 108.2%   
Low Rs579433 133.7%   
Sales per share (Unadj.) Rs228.4110.4 206.9%  
Earnings per share (Unadj.) Rs31.711.0 289.1%  
Cash flow per share (Unadj.) Rs32.817.2 190.2%  
Dividends per share (Unadj.) Rs10.002.00 500.0%  
Dividend yield (eoy) %1.50.4 424.0%  
Book value per share (Unadj.) Rs297.1158.8 187.1%  
Shares outstanding (eoy) m24.692,399.26 1.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.95.1 57.0%   
Avg P/E ratio x21.151.6 40.8%  
P/CF ratio (eoy) x20.432.9 62.0%  
Price / Book Value ratio x2.23.6 63.0%  
Dividend payout %31.518.2 172.9%   
Avg Mkt Cap Rs m16,5051,360,021 1.2%   
No. of employees `0000.717.8 3.8%   
Total wages/salary Rs m1,44553,671 2.7%   
Avg. sales/employee Rs Th8,441.314,890.9 56.7%   
Avg. wages/employee Rs Th2,163.63,017.1 71.7%   
Avg. net profit/employee Rs Th1,173.11,480.6 79.2%   
INCOME DATA
Net Sales Rs m5,639264,895 2.1%  
Other income Rs m1,7188,388 20.5%   
Total revenues Rs m7,357273,282 2.7%   
Gross profit Rs m-6356,081 -0.1%  
Depreciation Rs m2514,998 0.2%   
Interest Rs m555,176 1.1%   
Profit before tax Rs m1,57544,295 3.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-9,505 0.0%   
Tax Rs m7928,452 9.4%   
Profit after tax Rs m78426,338 3.0%  
Gross profit margin %-1.121.2 -5.2%  
Effective tax rate %50.319.1 263.4%   
Net profit margin %13.99.9 139.8%  
BALANCE SHEET DATA
Current assets Rs m9,522316,359 3.0%   
Current liabilities Rs m3,296198,643 1.7%   
Net working cap to sales %110.444.4 248.4%  
Current ratio x2.91.6 181.4%  
Inventory Days Days3795 38.6%  
Debtors Days Days28108 26.4%  
Net fixed assets Rs m46213,178 0.0%   
Share capital Rs m1232,399 5.1%   
"Free" reserves Rs m7,213378,606 1.9%   
Net worth Rs m7,336381,006 1.9%   
Long term debt Rs m017,721 0.0%   
Total assets Rs m11,105643,028 1.7%  
Interest coverage x29.59.6 308.5%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.4 123.3%   
Return on assets %7.64.9 154.1%  
Return on equity %10.76.9 154.5%  
Return on capital %22.210.0 221.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6140,816 0.1%   
Fx outflow Rs m3,63030,143 12.0%   
Net fx Rs m-3,57010,673 -33.4%   
CASH FLOW
From Operations Rs m1,61039,072 4.1%  
From Investments Rs m687-33,708 -2.0%  
From Financial Activity Rs m-2,677-15,393 17.4%  
Net Cashflow Rs m-380-7,359 5.2%  

Share Holding

Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 5.1 39.0%  
FIIs % 1.6 23.0 7.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 8.3 259.0%  
Shareholders   41,647 133,026 31.3%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   WYETH LTD  IPCA LABS  NATCO PHARMA  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Open Flat; Pharma Stocks Gain(09:30 am)

Asian share markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.5% while the Hang Seng is up 1%.

Related Views on News

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 19, 2018 | Updated on Sep 19, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 446.1% (Quarterly Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

For the quarter ended June 2018, SUN PHARMA has posted a net profit of Rs 11 bn (up 446.1% YoY). Sales on the other hand came in at Rs 72 bn (up 16.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Sep 26, 2018 10:37 AM

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS